

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain) September 10, 2024

OTHER RELEVANT INFORMATION

In accordance with the provisions set forth in Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), submits hereafter press release regarding the announcement of the opening of the REIG JOFRE CZECH REPUBLIC subsidiary in the Czech Republic.

Yours faithfully,

Adolf Rousaud
Secretary non director of the Board of Directors
Laboratorio Reig Jofre SA

BARCELONA (Spain), September 10, 2024

REIG JOFRE STRENGTHENS ITS INTERNATIONAL EXPANSION WITH THE OPENING OF A NEW SUBSIDIARY IN THE CZECH REPUBLIC

- REIG JOFRE expands its presence in Eastern Europe with the opening of its RJ Czech Republic subsidiary, initially focused on osteoarticular health and dermatology products. The company began its operations in the second half of 2024.

REIG JOFRE, (BME:RIF), a publicly listed pharmaceutical company on the Spanish stock exchange, which researches, develops, manufactures, and markets essential pharmaceutical products for human health, continues its international growth strategy with the opening of a new subsidiary in the Czech Republic, where it already operates through distribution agreements.

The new subsidiary, **RJ Czech Republic**, will have a specialized commercial team focused on the pharmaceutical market and will collaborate with a local partner, LERAM Pharma. From this subsidiary, the company will provide products in the osteoarticular health and dermatology segments through its *Specialty Pharmacare* unit. In 2023, the Czech prescription market for musculoskeletal products reached €175 million, while the dermatology segment totaled €77 million, both experiencing double-digit growth. With the introduction of its innovative products, the company aims to further drive growth in these sectors, delivering differentiated value that enhances patients' quality of life and strengthens its leadership in these therapeutic areas.

In a second phase, RJ Czech Republic will gradually introduce products from the *Consumer Healthcare* unit, which includes ranges for weight control, energy, stress and sleep management, and beauty. In the future, the company plans to incorporate the rest of its products, including hospital injectables from the *Pharmaceutical Technologies* unit, once the necessary registration processes in the Czech market are completed.

REIG JOFRE's expansion is focused on internationalization as a key growth driver, supported by the establishment of subsidiaries in strategic European markets and the formalization of distribution agreements in key countries. Following the opening of its Polish subsidiary in 2021, which marked a significant step forward in Eastern Europe, the company is now extending its business model to the Czech Republic, with the first sales expected in the second half of 2024. This move strengthens its presence in strategic markets and consolidates its global growth plan.

Currently, 55% of REIG JOFRE's international revenue comes from its own sales network in Europe, which includes Spain, France, Portugal, Belgium, Sweden, the United Kingdom, Poland, and soon, the Czech Republic. Additionally, the company has an extensive network of commercial partners in over 70 countries.

Reig Jofre closed 2023 with sales of €316 million and an EBITDA of €35 million. The Specialty Pharmacare (osteoarticular and dermatology) and Consumer Healthcare units accounted for 33% and 23% of the total, respectively.

Further information

Inma Santa-Pau – Director of Communication and Public Relations - isantapau@reigjofre.com

www.reigjofre.com



About REIG JOFRE

REIG JOFRE is a pharmaceutical company born with the firm conviction of universalizing health, providing basic to innovative solutions to people worldwide. To deliver pioneering and high-impact solutions, they boast cutting-edge technological production and maintain continuous collaboration with other innovative companies, researchers, and startups, while constantly investing in R&D. Since 1929, they have been researching, developing, manufacturing, and marketing pharmaceutical products essential for people's health, under three major areas: Pharmaceutical Technologies, Specialty Pharmacare, and Consumer Healthcare. REIG JOFRE has four development and production centers in Europe, with its own teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, and Poland, along with an extensive network of business partners in over 70 countries and over 1,300 employs. The company closed 2023 with a turnover of €316M (+17% vs. 2022) and an EBITDA of €35M (+15% vs. 2022) and is listed on the continuous market of the Spanish stock exchange under the ticker RJF.